{"id":221296,"date":"2023-11-09T09:57:32","date_gmt":"2023-11-09T09:57:32","guid":{"rendered":"https:\/\/bm.dev.synology.me\/?p=221296"},"modified":"2023-11-09T09:57:32","modified_gmt":"2023-11-09T09:57:32","slug":"fda-a-aprobat-medicamentul-lilly-pentru-pierderea-in-greutate","status":"publish","type":"post","link":"https:\/\/bm.dev.synology.me\/?p=221296","title":{"rendered":"FDA a aprobat medicamentul Lilly pentru pierderea \u00een greutate"},"content":{"rendered":"<p>\nFDA a aprobat tirzepatida, care va fi v\u00e2ndut\u0103 sub numele de marc\u0103 Zepbound, pentru a fi utilizat\u0103 de c\u0103tre adul\u0163ii cu un indice de mas\u0103 corporal\u0103 (IMC) de cel pu\u0163in 30, sau un IMC de 27 sau mai mare dac\u0103 pacientul are \u015fi o alt\u0103 problem\u0103 de s\u0103n\u0103tate legat\u0103 de greutate, cum ar fi bolile de inim\u0103.<\/p>\n<p>\n\u201eObezitatea \u015fi excesul de greutate sunt afec\u0163iuni grave care pot fi asociate cu unele dintre principalele cauze de deces, cum ar fi bolile de inim\u0103, accidentele vasculare cerebrale \u015fi diabetul\u201d, a declarat \u00eentr-un comunicat John Sharretts, director \u00een cadrul Centrului pentru evaluarea \u015fi cercetarea medicamentelor din cadrul FDA.<\/p>\n<p>\nTirzepatida este deja aprobat\u0103 sub denumirea comercial\u0103 Mounjaro pentru diabetul de tip 2 \u015fi fusese din ce \u00een ce mai mult utilizat\u0103 \u201eoff-label\u201d pentru pierderea \u00een greutate \u00een timp ce aprobarea pentru obezitate era \u00een curs de aprobare.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Administra\u0163ia american\u0103 pentru Alimente \u015fi Medicamente a aprobat miercuri medicamentul Eli Lilly pentru pierderea \u00een greutate, oferind astfel produc\u0103torului american de medicamente intrarea oficial\u0103 pe o pia\u0163\u0103 profitabil\u0103 care a captat entuziasmul Wall Street \u00een acest an.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[510],"tags":[5809,23968,10082],"class_list":["post-221296","post","type-post","status-publish","format-standard","hentry","category-actualitate","tag-da","tag-greutate","tag-lilly"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/221296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=221296"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/221296\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=221296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=221296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=221296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}